- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00077974
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Studieöversikt
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010-3000
- Pfizer Investigational Site
-
Pasadena, California, Förenta staterna, 91105
- Pfizer Investigational Site
-
San Francisco, California, Förenta staterna, 94115
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Pfizer Investigational Site
-
Boston, Massachusetts, Förenta staterna, 02115
- Pfizer Investigational Site
-
Boston, Massachusetts, Förenta staterna, 02215
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Pfizer Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Pfizer Investigational Site
-
-
New York
-
New York, New York, Förenta staterna, 10021
- Pfizer Investigational Site
-
New York, New York, Förenta staterna, 10022
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97213
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19111
- Pfizer Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792
- Pfizer Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Cytokine refractory metastatic renal cell carcinoma with clear cell component
- Radiographic evidence of disease progression during or within 9 months of completion of 1 cytokine therapy
- Prior nephrectomy
Exclusion Criteria:
- Prior treatment with any systemic therapy other than 1 cytokine therapy
- History of or known brain metastases
- Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study start
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: 1
|
50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)
Tidsram: From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
|
Overall confirmed objective response = confirmed Complete Response (CR) or confirmed Partial Response (PR) according to RECIST.
CR defined as disappearance of all target lesions.
PR defined as >= 30 percent decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
|
From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to Tumor Progression (TTP)
Tidsram: From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
|
Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first.
TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]).
|
From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter
|
|
Duration of Response (DR)
Tidsram: Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death due to cancer
|
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of patients with a confirmed objective tumor response. |
Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death due to cancer
|
|
Overall Survival (OS)
Tidsram: From start of study treatment until death
|
Time in weeks from the start of study treatment to date of death due to any cause.
OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the subject current status was death).
|
From start of study treatment until death
|
|
Progression-free Survival (PFS)
Tidsram: From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death
|
Time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause.
PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was "Death").
|
From start of study treatment until Day 28 of Cycles 1-5, Day 28 of even Cycles thereafter or death
|
|
Percent Chance of Patient Survival
Tidsram: From start of study treatment until death
|
Probability of survival 1 year and 2 years after the first dose of study treatment
|
From start of study treatment until death
|
|
Observed Plasma Trough Concentrations of Sunitinib
Tidsram: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Observed plasma trough (predose) (Cmin) concentrations of sunitinib
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Observed Plasma Trough Concentrations of Sunitinib Metabolite
Tidsram: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Observed plasma trough (predose) (Cmin) concentrations of sunitinib metabolite (SU012662)
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Observed Plasma Trough Concentrations of Sunitinib Plus Metabolite
Tidsram: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Observed plasma trough (predose) concentrations of sunitinib plus its metabolite (SU012662)
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Dose Corrected Plasma Trough Concentrations of Sunitinib
Tidsram: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib.
Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date.
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Dose Corrected Plasma Trough Concentrations of Sunitinib Metabolite
Tidsram: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib metabolite (SU012662).
Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date.
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
|
Dose Corrected Plasma Trough Concentrations of Sunitinib Plus Metabolite
Tidsram: Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Dose corrected plasma trough (predose) (Cmin) concentrations of sunitinib plus its metabolite (SU012662).
Dose-corrected trough concentrations were set to missing for trough samples collected outside acceptable times from dose administration, samples not collected within scheduled day range, samples with missing collection or administration dates or times, samples collected with dose interruption, and samples collected with inconsistent dose level within 10 days of last dose date.
|
Day 28 of Cycle 1 through 4, Day 1 of Cycles 5 and greater
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
- Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.
- Grunwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May;67(5):952-8. doi: 10.1016/j.eururo.2014.12.036. Epub 2015 Jan 7.
- Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Jun 7;295(21):2516-24. doi: 10.1001/jama.295.21.2516.
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Urologiska neoplasmer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Njursjukdomar
- Urologiska sjukdomar
- Adenocarcinom
- Neoplasmer, körtel och epitel
- Neoplasmer i njurarna
- Karcinom, njurcell
- Carcinom
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Proteinkinashämmare
- Sunitinib
Andra studie-ID-nummer
- A6181006
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .